Friday, April 29, 2011
Otonomy Inc., of San Diego, reported positive data from a Phase Ib study of the company's lead product candidate, OTO-104, in patients with Ménière's disease. Study results showed OTO-104 to be well-tolerated at both doses tested when delivered via a single intratympanic injection. Additionally, while not powered to demonstrate statistically significant clinical activity, data from the trial showed that patients receiving OTO-104 experienced greater reductions in vertigo frequency and tinnitus compared to patients receiving placebo.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.